Avastin no longer allowed for breast cancer

The U.S. Food & Drug Administration has revoked its approval of Avastin after concluding the metastatic breast cancer treatment did nothing to control tumor growth or help patients live longer, but instead increased their risk of developing severe high blood pressure, hemorrhages and other serious side effects.

European Medicines Agency remains cautious toward pioglitazone, but hesitates to issue outright ban despite Actos bladder cancer evidence

(Oct. 25, 2011)  After earlier sending signals that it might move to outlaw the drug pioglitazone (Actos), the European Medical Agency backed off last week from recommending any such ban on the grounds that Type 2 diabetics who respond only to this particular pharmaceutical should not lose access to it, despite mounting evidence linking Actos to bladder cancer.

Are storm clouds already gathering over Pradaxa?Critics of blood-thinner drug troubled by events in New Zealand

(Oct. 18, 2011) If some safety advocates are correct, a drug worth keeping a skeptical eye on is the blood thinner Pradaxa because of its propensity to increase the risk of bleeding – perhaps fatally so, according to the manufacturer’s own label warning.

Already, in New Zealand, Pradaxa is tied to at least two deaths amid reports that scores of elderly users there experienced bleeding ranging from mild to severe.